Fimasartan

Drug Profile

Fimasartan

Alternative Names: Arakhor; BR-A-657; BR-A-657-K; Kanarb

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boryung
  • Developer Boryung; Covance; R-Pharm
  • Class Antihypertensives; Pyrimidinones; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Essential hypertension; Hypertension

Highest Development Phases

  • Marketed Essential hypertension; Hypertension
  • Phase III Kidney disorders
  • Preclinical Diabetic nephropathies; Myocardial infarction

Most Recent Events

  • 16 Aug 2017 Boryung Pharmaceutical completed enrolment in a phase I trial for Hypertension (In volunteers) in South Korea (NCT03250052)
  • 07 Aug 2017 Phase-III clinical trials in Essential hypertension (In the elderly) in South Korea (PO) (NCT03246555)
  • 29 Jul 2017 Boryung Pharmaceutical initiates enrolment in a phase I trial for Hypertension (In volunteers) in South Korea (NCT03250052)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top